Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 18/20 | 0.44 |
| ▸ | SLC2A3 | P11169 | 18/20 | 0.44 |
| ▸ | SLC2A4 | P14672 | 18/20 | 0.44 |
| ▸ | SLC2A2 | P11168 | 8/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16832331 | 0.86 | SLC2A1 (0.43) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 | |
| SCHEMBL18482888 | 0.83 | CYP11B1 (0.43) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL16833028 | 0.82 | DCTPP1 (0.41) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 | |
| SCHEMBL16832309 | 0.77 | SLC2A1 (0.52) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 | |
| SCHEMBL16832841 | 0.75 | GAA (0.47) | SLC2A1SLC2A3SLC2A4CYP19A1CYP11B1 | |
| SCHEMBL16833222 | 0.72 | SLC2A1 (0.44) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 | |
| SCHEMBL16833019 | 0.72 | SLC2A1 (0.48) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 | |
| SCHEMBL18482887 | 0.72 | SLC2A1 (0.44) | SLC2A1SLC2A3SLC2A4SLC2A2CYP19A1 | |
| SCHEMBL16832838 | 0.72 | SLC2A1 (0.39) | SLC2A1SLC2A3SLC2A4SLC2A2ADORA3 | |
| SCHEMBL16832906 | 0.71 | MAPT (0.50) | CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | SLC2A1 1/4885SLC2A3 4/4885SLC2A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.